LIBOURNE, France, February 9, 2017 /PRNewswire/ --
2016 was a yearofsustained organic growth and major acquisitions. Consolidated sales reached€912m as the Ceva Group continuedto achievedouble-digit growth.
Virtuous growth consolidated
Consolidated sales of the Ceva Group reached €912 million in 2016, demonstrating growth of 10% compared to 2015 at constant scope and exchange rate.
Group sales by region were as follows: Europe (36%); AMEET (Africa, Middle East, Eastern Europe, Russia, Ukraine, Turkey) (23%); North America/Pacific (17%); Asia (11%) and Latin America (12%). Ceva experienced good growth in all markets.
Ceva's product portfolio performed well across all species, especially poultry and swine.
"2016 was asignificant year for Ceva withdouble-digit growthachievedonce again, testifying to the soundness of our business model. With the acquisition of some key products from Merial and reinforcement of our position in key strategic markets, we have the responsibilityto deliver more value from these excellent new assets." Dr Marc Prikazsky, Ceva's Chairman & CEO
2016:yearofstrategicacquisitions
Since its inception in 2000, Ceva has acquired more than 30 companies, providing the group with a strong foothold in key markets and boosting its product portfolio and expertise. This year, the group deployed an aggressive external growth strategy, concluding several major acquisitions across the globe:
ththIn its home market of France, the group made further acquisitions:
Finally, with the purchase ofseveral formerMerial products in late January 2017, Ceva will consolidate its position in the international swine vaccines market and develop its range of non-steroidal anti-inflammatories.
"The challenge now is to consolidate these acquisitions to makesure they areallsuccessful.In 2017 we willpursue ourinternationalambitions,most likelythroughnew acquisitions. After India and South America, we shouldbestrengthening our position inAsia," Dr Prikazsky added.
Ceva to invest heavily in 2017 toreach the top 5 by2020
"Our priority for 2017 is to continue ourvirtuous growth cycle,to deliver morevalue for our customers,forthe society in which we live andultimately forCeva," affirmed Dr. Prikazsky.
While developing our foothold in various markets, Ceva will also continue to make significant investment inits industrialfacilities. In 2017 the Group plans to devote more than €90 million to enlarge its main production sites.
ABOUT CEVA SANTÉ ANIMALE
Ceva Santé Animale is a global veterinary health company, focused on research, development, production and sales of pharmaceutical products and vaccines for companion animals, livestock, swine and poultry.
Present in 110 countries, Ceva Santé Animale employs more than 4,500 people around the world.
https://www.facebook.com/CevaFrance/?fref=ts
https://mobile.twitter.com/Ceva_France
https://www.linkedin.com/company/ceva-sante-animale
https://www.youtube.com/user/CevaTV1
CevaSantéAnimale -Martin Mitchell - Group Communication Director - Tel. +33-05-57-55-40-80 - martin.mitchell@ceva.com
